Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics
Werte in diesem Artikel
Wall Street analysts forecast that Illumina (ILMN) will report quarterly earnings of $0.96 per share in its upcoming release, pointing to a year-over-year increase of 966.7%. It is anticipated that revenues will amount to $1.04 billion, exhibiting a decline of 3.5% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Given this perspective, it's time to examine the average forecasts of specific Illumina metrics that are routinely monitored and predicted by Wall Street analysts.Analysts expect 'Revenue- Product revenue- Consumable' to come in at $763.09 million. The estimate indicates a year-over-year change of +0.1%.The consensus estimate for 'Revenue- Service and other revenue' stands at $170.12 million. The estimate suggests a change of -14.9% year over year.Analysts predict that the 'Revenue- Product revenue' will reach $872.04 million. The estimate indicates a year-over-year change of -0.5%.Based on the collective assessment of analysts, 'Revenues- Core Illumina- Service and other revenue' should arrive at $175.08 million. The estimate indicates a year-over-year change of +1.2%.The consensus among analysts is that 'Revenues- Core Illumina- Total product revenue' will reach $869.69 million. The estimate suggests a change of -1.5% year over year.The combined assessment of analysts suggests that 'Revenue- Product revenue- Instruments' will likely reach $108.95 million. The estimate indicates a change of -4.4% from the prior-year quarter.Analysts' assessment points toward 'Revenues- Core Illumina- Consumables' reaching $748.87 million. The estimate indicates a change of -2.6% from the prior-year quarter.According to the collective judgment of analysts, 'Revenue- Sequencing- Instruments' should come in at $108.51 million. The estimate points to a change of -1.4% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Revenue- Sequencing- Consumables' of $679.85 million. The estimate suggests a change of -2.6% year over year.It is projected by analysts that the 'Revenue- Microarrays- Instruments' will reach $3.61 million. The estimate indicates a change of -9.9% from the prior-year quarter.The average prediction of analysts places 'Revenue- Microarrays- Consumables' at $74.59 million. The estimate indicates a year-over-year change of +5.1%.Analysts forecast 'Revenue- Core Illumina' to reach $1.03 billion. The estimate indicates a year-over-year change of -2.1%.View all Key Company Metrics for Illumina here>>>Shares of Illumina have demonstrated returns of +5% over the past month compared to the Zacks S&P 500 composite's +0.4% change. With a Zacks Rank #3 (Hold), ILMN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Illumina und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Illumina
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Illumina
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Illumina Inc.
Analysen zu Illumina Inc.
Datum | Rating | Analyst | |
---|---|---|---|
30.07.2019 | Illumina Hold | Canaccord Adams | |
30.05.2019 | Illumina Outperform | Wolfe Research | |
09.10.2018 | Illumina Neutral | UBS AG | |
31.07.2018 | Illumina Buy | Canaccord Adams | |
31.01.2018 | Illumina Overweight | First Analysis Securities |
Datum | Rating | Analyst | |
---|---|---|---|
30.05.2019 | Illumina Outperform | Wolfe Research | |
31.07.2018 | Illumina Buy | Canaccord Adams | |
31.01.2018 | Illumina Overweight | First Analysis Securities | |
25.10.2017 | Illumina Outperform | Robert W. Baird & Co. Incorporated | |
23.10.2017 | Illumina Buy | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
30.07.2019 | Illumina Hold | Canaccord Adams | |
09.10.2018 | Illumina Neutral | UBS AG | |
05.01.2018 | Illumina Neutral | BTIG Research | |
02.08.2017 | Illumina Equal-Weight | First Analysis Securities | |
26.04.2017 | Illumina Neutral | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
02.11.2016 | Illumina Underweight | First Analysis Securities |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Illumina Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen